. . "Indomethacin"@en . . . . "The following symptoms may be observed following overdosage: nausea, vomiting, intense headache, dizziness, mental confusion, disorientation, or lethargy. There have been reports of paresthesias, numbness, and convulsions. The oral LD₅₀ of indomethacin in mice and rats (based on 14 day mortality response) was 50 and 12 mg/kg, respectively."@en . "Indomethacin is eliminated via renal excretion, metabolism, and biliary excretion."@en . "97%"@en . "Indometacina"@en . "Indocin"@en . . . . "Humans and other mammals"@en . . . . . . "53-86-1"@en . . . . . . . . . . . . . . . . . " "@en . . . . . . . . . . . . . . . . . . . . . . . "investigational"@en . . . . . . "Avoid alcohol."@en . "Indometacinum"@en . . . . . . . "1-(p-chlorobenzoyl)-5-methoxy-2-methylindole-3-acetic acid"@en . . "Bioavailability is approximately 100% following oral administration and 80\u201390% following rectal administration."@en . . "Indometacin"@en . . . . . . . . . . . "4.5 hours"@en . . "Indometacine"@en . . . . . . . "approved"@en . . . . . . . . . . . . . "Indomethacin is a non-steroidal antiinflammatory agent (NSAIA) with antiinflammatory, analgesic and antipyretic activity. Its pharmacological effect is thought to be mediated through inhibition of the enzyme cyclooxygenase (COX), the enzyme responsible for catalyzes the rate-limiting step in prostaglandin synthesis via the arachidonic acid pathway. "@en . "Take with food or antacids to reduce irritation."@en . "Indomethacin"@en . . . . . . . . . . . . . . . . "Hubertus L. Regtop, John R. Biffin, \"Preparation of divalent metal salts of indomethacin.\" U.S. Patent US5310936, issued November, 1917."@en . . . . . . . . "Aconip"@en . . . . . . . . . . . . . . . . . . . . . . . "# Akbarpour F, Afrasiabi A, Vaziri ND: Severe hyperkalemia caused by indomethacin and potassium supplementation. South Med J. 1985 Jun;78(6):756-7. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/4002013 # HART FD, BOARDMAN PL: INDOMETHACIN: A NEW NON-STEROID ANTI-INFLAMMATORY AGENT. Br Med J. 1963 Oct 19;2(5363):965-70. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/14056924 # Lum GM, Aisenbrey GA, Dunn MJ, Berl T, Schrier RW, McDonald KM: In vivo effect of indomethacin to potentiate the renal medullary cyclic AMP response to vasopressin. J Clin Invest. 1977 Jan;59(1):8-13. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/187624 # Phelan KM, Mosholder AD, Lu S: Lithium interaction with the cyclooxygenase 2 inhibitors rofecoxib and celecoxib and other nonsteroidal anti-inflammatory drugs. J Clin Psychiatry. 2003 Nov;64(11):1328-34. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/14658947 # Ragheb M: The clinical significance of lithium-nonsteroidal anti-inflammatory drug interactions. J Clin Psychopharmacol. 1990 Oct;10(5):350-4. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/2258452"@en . . . . . . "Indomethacin is a prostaglandin G/H synthase (also known as cyclooxygenase or COX) inhibitor that acts on both prostaglandin G/H synthase 1 and 2 (COX-1 and -2). Prostaglandin G/H synthase catalyzes the conversion of arachidonic acid to a number of prostaglandins involved in fever, pain, swelling, inflammation, and platelet aggregation. Indomethacin antagonizes COX by binding to the upper portion of the active site, preventing its substrate, arachidonic acid, from entering the active site. Indomethacin, unlike other NSAIDs, also inhibits phospholipase A2, the enzyme responsible for releasing arachidonic acid from phospholipids. Indomethacin is more selective for COX-1 than COX-2, which accounts for its increased adverse gastric effects relative to other NSAIDs. COX-1 is required for maintaining the protective gastric mucosal layer. The analgesic, antipyretic and anti-inflammatory effects of indomethacin occur as a result of decreased prostaglandin synthesis. Its antipyretic effects may be due to action on the hypothalamus, resulting in an increased peripheral blood flow, vasodilation, and subsequent heat dissipation."@en . . . . . . . . . . . . . . . . . . . . . "For moderate to severe rheumatoid arthritis including acute flares of chronic disease, ankylosing spondylitis, osteoarthritis, acute painful shoulder (bursitis and/or tendinitis) and acute gouty arthritis."@en . . . . "{1-[(4-chlorophenyl)carbonyl]-5-methoxy-2-methyl-1H-indol-3-yl}acetic acid"@en .